tradingkey.logo

Regenxbio Announces FDA Review Extension Of BLA For RGX-121 To Treat Patients With MPS II

ReutersAug 18, 2025 10:13 PM

- Regenxbio Inc RGNX.O:

  • REGENXBIO ANNOUNCES FDA REVIEW EXTENSION OF BLA FOR RGX-121 TO TREAT PATIENTS WITH MPS II

  • REGENXBIO INC - PDUFA DATE EXTENDED TO FEBRUARY 8, 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI